Truist Securities Reiterates Hold on Integra Lifesciences, Lowers Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reiterated a Hold rating on Integra Lifesciences (NASDAQ:IART) and lowered the price target from $54 to $44.
May 30, 2023 | 11:59 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities analyst Richard Newitter reiterated a Hold rating on Integra Lifesciences (NASDAQ:IART) and lowered the price target from $54 to $44.
The lowered price target from $54 to $44 by Truist Securities analyst Richard Newitter indicates a less optimistic outlook for Integra Lifesciences. This could lead to a negative short-term impact on the stock price as investors may adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100